Acrivastine
Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine (like its base molecule triprolidine) and works by blocking histamine H1 receptors.
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 1.5 hours |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.110.306 |
| Chemical and physical data | |
| Formula | C22H24N2O2 |
| Molar mass | 348.446 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
| |
| (what is this?) (verify) | |
This non-sedating antihistamine is sold under the brand name Benadryl Allergy Relief in the United Kingdom by McNeil Laboratories. It should not be confused with Benadryl Once a Day which has cetirizine as the active ingredient and is also sold by McNeil in the UK, nor with the American Benadryl, which uses diphenhydramine as its active ingredient. It is available as an over-the-counter medicine in the UK, and is available with or without pseudoephedrine under the Benadryl brand.
In the U.S., acrivastine was the active ingredient in the Semprex brand. Semprex-D also contains the decongestant pseudoephedrine. Semprex-D was marketed in the U.S. by Actient Pharmaceuticals. Neither version of Semprex have been manufactured for sale in the US since 2008.